title: Failure of somatostatin to affect human chorionic somatomammotropin and human chorionic gonadotropin secretion in vitro.
abstract: The effect of somatostatin (SRIF) on human chorionic somatomammotropin (hCS) secretion was studied in human placental explants cultured in vitro. In the experimental flasks, SRIF was added in a concentration of 10, 100, and 1000 ng/ml media; hCS levels measured by RIA were not different from those found in the control flasks. In separate experiments, we investigated the action of SRIF on hCG secretion by a human malignant choriocarcinoma cell line maintained in tissue culture. SRIF (1000 ng/ml) did not inhibit basal or dibutyryl cAMP-induced stimulation of hCG secretion. These results suggest that somatostatin does not suppress hCS or hCG release in vitro from normal or malignant trophoblast, respectively.
mesh_terms: D003994:Bucladesine / Q000494:pharmacology; D002460:Cell Line; D002822:Choriocarcinoma / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D005260:Female; D006801:Humans; D009924:Organ Culture Techniques; D010920:Placenta / Q000187:drug effects / Q000378:metabolism*; D010928:Placental Lactogen / Q000378:metabolism*; D011247:Pregnancy; D013004:Somatostatin / Q000494:pharmacology*; D014594:Uterine Neoplasms / Q000378:metabolism
chemical_list: D006063:Chorionic Gonadotropin; D013004:Somatostatin; D003994:Bucladesine; D010928:Placental Lactogen